HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- ((5- chloro- 2- hydroxyphenyl)methyl)- 5- (4- (trifluoromethyl)phenyl)- 1,3,4- oxadiazol- 2(3H)- one

a maxi-K channel opener; structure in first source

Also Known As:

BMS 191011; BMS-191011; BMS191011

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        3-((5-chloro-2-hydroxyphenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one: 4

Experts

1.	Cai, Hui: 1 article (01/2022)
2.	Eaton, Douglas C: 1 article (01/2022)
3.	Farris, Alton B: 1 article (01/2022)
4.	Jiang, Gengru: 1 article (01/2022)
5.	Ning, Fengling: 1 article (01/2022)
6.	Ren, Dadui: 1 article (01/2022)
7.	Tao, Jie: 1 article (01/2022)
8.	Wang, Mengling: 1 article (01/2022)
9.	Wang, Yinhang: 1 article (01/2022)
10.	Xie, Weiyi: 1 article (01/2022)

Related Diseases

1.	Stroke (Strokes) 05/19/2003 - "Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection."
2.	Tinnitus 01/01/2022 - "Thus, action of BMS-191011 in the inferior colliculus may contribute to the reduction in behaviorally measured tinnitus. " 01/01/2022 - "Systemic BMS-191011 treatment did not influence SS-induced increases in auditory brainstem response functions, but local application at the inferior colliculus did reverse SS-suppressed spontaneous activity, particularly in the frequency region of the tinnitus percept. " 01/01/2022 - "Systemic treatment with BMS-191011 reduced behavioral manifestations of SS-induced tinnitus, but not hyperacusis, probed via the gap-in-noise startle response method. " 01/01/2022 - "To test whether BK channel openers are able to suppress biomarkers of drug-induced tinnitus and hyperacusis, the 1,3,4 oxadiazole BMS-191011 was given to young adult CBA mice that had been administered 250 mg/kg sodium salicylate (SS). "
3.	Hyperacusis (Phonophobia) 01/01/2022 - "Systemic treatment with BMS-191011 reduced behavioral manifestations of SS-induced tinnitus, but not hyperacusis, probed via the gap-in-noise startle response method. " 01/01/2022 - "To test whether BK channel openers are able to suppress biomarkers of drug-induced tinnitus and hyperacusis, the 1,3,4 oxadiazole BMS-191011 was given to young adult CBA mice that had been administered 250 mg/kg sodium salicylate (SS). "
4.	Melanoma (Melanoma, Malignant) 12/06/2021 - "Here, we investigated the effects of different BK activators, NS-11021, NS-19504, and BMS-191011, in IGR39 (primary melanoma cell line) and Panc-1 (primary pancreatic duct carcinoma cell line), highly expressing the channel, and in IGR37 (metastatic melanoma cell line) that barely express BK. "
5.	Fibrosis (Cirrhosis) 01/01/2022 - "Activation of BK activity by chemical NS1619 or BMS191011 channel openers attenuated kidney fibrosis in these two models while protecting kidney function in wild-type mice. "

Related Drugs and Biologics

1.	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)
2.	Biomarkers (Surrogate Marker)
3.	Sodium Salicylate (Salicylate, Sodium)
4.	Prodrugs
5.	Oxadiazoles
6.	1- (3,5- bis(trifluoromethyl)phenyl)- 3- (4- bromo- 2- (1H- tetrazol- 5- yl)phenyl)thiourea
7.	NS 1619